Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people. While it is well known for causing muscle weakness and stiffness, DM1 also ...

The RNA Institute is located at the University at Albany's uptown campus in Albany, where the Wellstone Center will also have a presence. ALBANY— The University at Albany and Virginia Commonwealth ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far. The Swiss pharma is paying $12 ...

Rachel Shatto, Editor-in-chief of PRIDE.com, is an SF Bay Area-based writer, podcaster, and former editor of Curve magazine, where she honed her passion for writing about social justice and sex (and ...

“Ozempic vulva" is an unoffcial term that women have been using to describe what they’ve been noticing in their genital areas after starting Ozempic or some other glucagon-like peptide-1 agonist.

They dropped — and then they drooped. Ozempic and other GLP-1 drugs have become extremely popular for their ability to manage Type 2 diabetes symptoms and spur weight loss. A recent study found that ...

A retrospective cohort study found that, among 459 patients with DMD, constipation (32.5%) was the most common GI complication, followed by dysphagia (9.4%). Older age, lower body mass index, and use ...

Physical activity and rehabilitation are key components of Duchenne muscular dystrophy treatment, despite recent drug therapy advances. "Rehabilitation care and rehabilitation teams with experience ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy. Sarepta reported the ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...